spacer
home > ebr > spring 2002 > harnessing the immune system against cancer
PUBLICATIONS
European Biopharmaceutical Review

Harnessing the Immune System Against Cancer

Cancerous cells contain numerous mutations, qualitative and quantitative, spatial and temporal, relative to their normal, non-cancerous counterparts. At certain periods during tumour cells' growth and spread, a proportion of these are capable of being recognised by the hosts' immune system as abnormal. This has led to numerous research efforts worldwide to develop immunotherapies that harness the power of the hosts' immune system and direct it to attack the cancerous cells, thereby eliminating such aberrant cells at least to a level that is not life-threatening (1,2). The market has recognised the potential of this approach, and the cancer vaccine revenues alone are forecast at US$3 billion by 2008 (3). Numerous approaches have been taken in the quest for cancer immunotherapies, which can be classified under the five categories covered in this article:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Anthony Walker, CEO of Onyvax Ltd

Prior to co-founding Onyvax in 1997, Anthony Walker spent 10 years as a Management Consultant, specialising in the pharmaceutical and biotechnology industries. During his eight years at Arthur D. Little, Anthony was appointed a European Director, responsible for the London-based pharmaceutical practice that he founded, and at The Wilkerson Group (London) he had responsibility for the UK, Benelux and Scandinavian markets.
Anthony has consulted to 12 of the top 25 Rx companies and has also worked closely with over 20 biotechnology companies. In addition, he has produced expert reports for a number of UK biotech IPOs.

spacer
Dr Anthony Walker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

EXTERNAL COMMUNICATION, 24 October 2019, Copenhagen, Denmark PRESS RELEASE – FLYPHARMA CONFERENCE EUROPE 2019

For its fifth annual Europe conference, FlyPharma chose Copenhagen as its host city to address the latest supply chain challenges and industry best practices, putting together a global audience of (bio)pharma and logistics professionals. The two-day conference (22-23 October 2019) aimed to discuss the collaboration and growth within Scandinavia, with a special focus on women in pharmaceutical logistics and an exploration of the industry’s digitalisation and innovation.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement